Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 7 October 2022, 10:00 HKT/SGT
Share:
    

Source: Novotech Health Holdings Pte Ltd
Novotech Selected as Scrip Awards Finalist for Best Full-Service CRO

SYDNEY, AU, Oct 7, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, joins a prestigious group of global CROs as a finalist in the Scrip Award for Best Full-Service CRO. This year the Award has been split into two categories to separate the full-service providers from the smaller CROs.

According to the Scrip Award organizers: "The Award for the Best CRO acknowledges the critical role that CROs play in drug development. Outsourcing is vital as the pharmaceutical industry seeks to benefit more and more from these specialist companies' experience in handling all aspects of clinical trials and other research. Today, the role of the CRO has gone beyond the traditional model of service-level agreements, to offer bespoke clinical trial and other strategies; and CROs are increasingly engaged in risk-sharing partnerships, or acting as a single-source developer, while also remaining committed to core strengths."

The award judges are senior executives from biopharma and investment firms, and clinical research leaders.

Novotech CEO Dr. John Moller said he was extremely pleased that Novotech has been selected as a finalist and thanked the global Novotech team for their hard work and commitment to a truly customer focused approach to accelerate clinical development.

"This level of recognition is a credit to the team and shows our Asia Pacific centered, global operations are setting new standards for biotech CRO partnerships. Our deep experience, exceptional site and investigator relationships - which also translates to patient access - our project management approach focused on problem-solving, ownership and flexibility, and our investments in data and technology combine to deliver the full service, customer focused solutions that biotechs need."

Novotech has operations across Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late phase biotech clinical research.

Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs and has also been selected for the Gene & Cell Therapy Excellence Award. The company also has more than 50 Leading Site Partnership agreements and hundreds of long-term site relationships across the Asia Pacific region.

About Novotech

Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contact

Media Contact
David James
E: communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427



Topic: Press release summary
Source: Novotech Health Holdings Pte Ltd

Sectors: BioTech, Healthcare & Pharm, Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Novotech Health Holdings Pte Ltd
Feb 15, 2023 09:00 HKT/SGT
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
Feb 10, 2023 19:00 HKT/SGT
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
Feb 3, 2023 13:00 HKT/SGT
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
Jan 12, 2023 15:00 HKT/SGT
Novotech Acquires European CRO, Strengthens Global Operations
Jan 12, 2023 15:00 HKT/SGT
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
Dec 20, 2022 11:00 HKT/SGT
Novotech is Gold Sponsor at Biotech Showcase 2023
Dec 15, 2022 10:00 HKT/SGT
Data Shows 50% of New Trials Have Sites in Asia Pacific
Dec 6, 2022 11:00 HKT/SGT
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
Nov 11, 2022 17:00 HKT/SGT
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
Oct 25, 2022 18:00 HKT/SGT
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: